Mastocytosis: Aiming for the Right Targets

We have witnessed important and historic developments in mastocytosis in the last year. Diagnostic criteria and classification of mastocytosis have been revised by the World Health Organization and International Consensus Classification groups. FDA approved avapritinib for the treatment of indolent systemic mastocytosis, the first cytoreductive targeted therapy with selectivity against D816V KIT mutation. Availability of new drugs made us think harder about coming up with symptom scores and quality-of-life measures to document response to therapies.
Source: Immunology and Allergy Clinics of North America - Category: Allergy & Immunology Authors: Tags: Preface Source Type: research